Repurposing Disulfiram as an Anti-Obesity Drug: Treating and Preventing Obesity in High-Fat-Fed Rats.
Aldh1a1
disulfiram
drug repurposing
obesity
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
03
2020
accepted:
18
04
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
A drug repurposing strategy is an approach for identifying new therapeutic uses for approved or investigational drugs. Thanks to the moderate cost of repurposing a drug compared to bringing new chemical entity to the market, drug repurposing is rapidly gaining ground. The aim of this work is to study the anti-obesity effect of disulfiram (DSF), an irreversible aldehyde dehydrogenase inhibitor approved by the Food and Drug Administration (FDA) to treat chronic alcoholism since 1951. Thirty male Albino rats were randomly assigned to six groups. G1, the control group, was given a standard diet. G2, the positive control group, was given a high-fat diet (HFD). G3 was given an HFD, and DSF 50 mg/kg/day was administered orally from day one for six weeks. G4 was given an HFD, and DSF 200 mg/kg/day was administered orally from day one for six weeks. G5 was given an HFD for six weeks; then treatment started with 50 mg/kg/day DSF orally. G6 was given an HFD for six weeks; then treatment started with 200 mg/kg/day DSF orally for three weeks. The body weight, food consumption and blood glucose levels were monitored over the given time interval. Both doses of DSF significantly limited the body weight gain caused by an HFD for the treated animals. HF-fed rats received 50 and 200 mg/kg/day of DSF had their body weight increased by 51.93 ± 7.89% and 20.88 ± 15.05% respectively, whereas the body weight of control animals increased by 93.1 ± 20.04%. DSF also significantly decreased the body weight of obese animals. At 50 and 200 mg/kg/day of DSF, HF-fed rats lost 16.74 ± 8.61% and 23.9 ± 3.93% respectively, as their untreated counterparts had their body weight increased by 11.85 ± 3.79% after three weeks of treatment, thus restoring a body weight matching those who received a standard diet. FDA-approved disulfiram has a strong anti-obesity effect on HFD-fed rats.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
A drug repurposing strategy is an approach for identifying new therapeutic uses for approved or investigational drugs. Thanks to the moderate cost of repurposing a drug compared to bringing new chemical entity to the market, drug repurposing is rapidly gaining ground. The aim of this work is to study the anti-obesity effect of disulfiram (DSF), an irreversible aldehyde dehydrogenase inhibitor approved by the Food and Drug Administration (FDA) to treat chronic alcoholism since 1951.
METHODS
METHODS
Thirty male Albino rats were randomly assigned to six groups. G1, the control group, was given a standard diet. G2, the positive control group, was given a high-fat diet (HFD). G3 was given an HFD, and DSF 50 mg/kg/day was administered orally from day one for six weeks. G4 was given an HFD, and DSF 200 mg/kg/day was administered orally from day one for six weeks. G5 was given an HFD for six weeks; then treatment started with 50 mg/kg/day DSF orally. G6 was given an HFD for six weeks; then treatment started with 200 mg/kg/day DSF orally for three weeks. The body weight, food consumption and blood glucose levels were monitored over the given time interval.
RESULTS
RESULTS
Both doses of DSF significantly limited the body weight gain caused by an HFD for the treated animals. HF-fed rats received 50 and 200 mg/kg/day of DSF had their body weight increased by 51.93 ± 7.89% and 20.88 ± 15.05% respectively, whereas the body weight of control animals increased by 93.1 ± 20.04%. DSF also significantly decreased the body weight of obese animals. At 50 and 200 mg/kg/day of DSF, HF-fed rats lost 16.74 ± 8.61% and 23.9 ± 3.93% respectively, as their untreated counterparts had their body weight increased by 11.85 ± 3.79% after three weeks of treatment, thus restoring a body weight matching those who received a standard diet.
CONCLUSION
CONCLUSIONS
FDA-approved disulfiram has a strong anti-obesity effect on HFD-fed rats.
Identifiants
pubmed: 32440176
doi: 10.2147/DMSO.S254267
pii: 254267
pmc: PMC7210036
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1473-1480Informations de copyright
© 2020 Omran et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Vis Exp. 2015 Jun 02;(100):e52806
pubmed: 26066392
J Agric Food Chem. 2016 Aug 24;64(33):6451-8
pubmed: 27499387
Can Med Assoc J. 1949 Mar;60(3):286-8
pubmed: 18110807
Int J Antimicrob Agents. 2020 Mar 20;:105949
pubmed: 32205204
Lancet. 2005 Oct 1;366(9492):1197-209
pubmed: 16198769
Mini Rev Med Chem. 2017;17(1):51-61
pubmed: 27320641
Nature. 2000 Apr 6;404(6778):635-43
pubmed: 10766250
Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
Endocrinology. 2012 Jul;153(7):3089-99
pubmed: 22555438
Q J Stud Alcohol. 1951 Jun;12(2):206-16
pubmed: 14844646
Am J Public Health. 2013 Oct;103(10):1895-901
pubmed: 23948004
Sci Rep. 2019 Oct 23;9(1):15177
pubmed: 31645582
Chem Biol Interact. 2003 Feb 1;143-144:201-10
pubmed: 12604205
Mol Cell Biol. 2003 Jul;23(13):4637-48
pubmed: 12808103
Nature. 2016 Jun 14;534(7607):314-6
pubmed: 27306171
Biomaterials. 2012 Aug;33(22):5638-49
pubmed: 22575837
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Adv Exp Med Biol. 2018;1075:285-318
pubmed: 30030798
Mol Pharmacol. 2004 Mar;65(3):675-84
pubmed: 14978246
Curr Obes Rep. 2013 Aug 30;2:320-326
pubmed: 24273701
Curr Pharm Des. 2019;25(30):3248-3256
pubmed: 31419930
J Nutr. 1993 Feb;123(2 Suppl):346-50
pubmed: 8429385
Adipocyte. 2015 Jul 15;5(1):11-21
pubmed: 27144092
Structure. 1998 Dec 15;6(12):1541-51
pubmed: 9862807
Nat Med. 2012 Jun;18(6):918-25
pubmed: 22561685
Nat Med. 2007 Jun;13(6):695-702
pubmed: 17529981
Antibiotics (Basel). 2019 May 30;8(2):
pubmed: 31151194
Clin Pharmacol Ther. 2019 Mar;105(3):692-702
pubmed: 30137649
Exp Biol Med (Maywood). 2013 May;238(5):491-501
pubmed: 23856900